Rhiniseng
Active substance
ATC code
Species
Pigs (sows and gilts).
Indications
For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella bronchiseptica and Pasteurella multocida infections during the fattening period.
Challenge studies have demonstrated that passive immunity lasts until piglets are 6 weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.
Dose to be administered and administration route
Intramuscular use.
Allow the vaccine to reach room temperature (15 ˚C - 25 ˚C) before administration.
Shake well before use.
Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:
Basic vaccination: sows and gilts which have not been previously vaccinated with the product should be given two injections with an interval of 3-4 weeks. The first injection should be administered 6-8 weeks before the expected date of farrowing.
Revaccination: a single injection should be given 3-4 weeks prior to each subsequent farrowing.
Adverse reactions
Pigs (sows and gilts):
Common (1 to 10 animals / 100 animals treated): | Injection site swelling1 Elevated temperature2 |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Anaphylactic-type reaction (severe allergic reaction)3 |
1After the administration of one dose of vaccine a swelling of less than 2 to 3 cm in diameter can occur at the injection site which may last up to five days and occasionally up to two weeks.
2An increase in body temperature of about 0.7 °C can occur during the first 6 hours after injection. An increase of rectal temperature up to 1.5º C may occur. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
3An appropriate symptomatic treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
